MTOR and hepatocellular carcinoma: Furthermore, a recent international prospective multicentre study (SRL in Liver Transplant Recipients with HCC study [SILVER]) that compared an mTOR inhibitor-based therapy with an mTOR inhibitor-free therapy reported a negative result [10].